Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Invivyd Inc IVVD

Healthcare Biotechnology
Invivyd, Inc. is a commercial-stage company, which is engaged in delivering antibody-based therapies. The Company’s proprietary INVYMAB platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:IVVD)

Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewswire 7 days ago

Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA(TM) (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor

GlobeNewswire 7 days ago

Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedRxiv and BioRxiv, Respectively

GlobeNewswire 9 days ago

Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference

GlobeNewswire November 6, 2024

Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024

GlobeNewswire November 6, 2024

Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability

GlobeNewswire October 29, 2024

Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA(TM) (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants

GlobeNewswire October 29, 2024

Invivyd to Present PEMGARDA(TM) (pemivibart) Data at Infectious Disease Week (IDWeek) 2024

GlobeNewswire October 16, 2024

Invivyd Announces U.S. FDA Has Updated the PEMGARDA(TM) EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data

GlobeNewswire October 1, 2024
View More News ››

Opinion & Analysis (NDAQ:IVVD)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:IVVD)

ADGI APPOINT DAVID HERING AS INTERIM CEO

EOM
Humanist - February 23, 2022

ADGI:TO ANALYZE DATA FROM TRIALS GLOBALLY/RESULTS END MARCH

BRIEF-Adagio Therapeutics Outlines Strategic Initiatives For Co's ADG20 Program   Published by  Reuters 2022 Feb...
Humanist - February 22, 2022

ADGI CEO RESIGNS/REPLACED BY COO INTERMILY

Adagio Therapeutics Announces CEO Succession Plan   https://finance.yahoo.com/news/adagio-therapeutics-announces-ceo-succession...
Humanist - February 19, 2022

Fekb 09, 2022

Nice price run up and volume. What will 4pm and rest of week say. What are we waiting to say ADGI...
petrojell - February 9, 2022

5 BIOTECH STOCKS WITH MAJOR UPCOMING CATALYSTS

$ADGI $CYTK $PHAT $AGIO $ICPT   Clinical-Stage companies offer an exciting investment opportunity with massive upside potential...
AviseAnalytics - February 8, 2022

any thoughts whats driving adgi tdy?

thx if you're reading this, would welcome all opinions
Humanist - February 7, 2022
View more Bullboard ››

Calima Energy Ord Shs

Calima Energy Ord Shs

Calima Energy Limited is an Australia-based production-focused energy company. The Company is engaged in the exploration and ...
View More »